baber/WOPTO huggingface dataset:
Patent NZ-546398-A (NZ)
Title: Infant formula
Inventor: SORENSEN ESBEN SKIPPER
IPC: A23L33/00
Filed: 2004-09-17
Abstract: Disclosed is the discovery that OPN is present in elevated levels in human breast milk compared to bovine milk. Previous estimations of the OPN content in milk have been based on Western blotting analyses and protein purification, i. e. 3-10 mg/litre. The development of a quantitative ELISA directed against milk OPN has lead to new insight into the concentration of OPN in milk. Accordingly the present invention provides infant formulas supplemented with milk osteopontin of mammalian origin, human and non-human. In all known infant formulas OPN can be included as supplement or OPN can be given to the infant separately from the formula which promote acquisition of Th1 response and thus reduce impaired immune function in infants.
Patent NZ-549907-A (NZ)
Title: Analysis of saccharide vaccines without interference
Inventor: BARDOTTI ANGELA
IPC: G01N33/569
Filed: 2005-03-17
Abstract: Disclosed is a process for analysing the saccharide content of a composition, wherein: (a) the composition comprises a capsular saccharide from serogroup C of Neisseria meningitidis and one or both of: (i) a capsular saccharide from serogroup W135ofNeisseria meningitidis ; and/or (ii) a capsular saccharide from serogroup Y of Neisseria meningitidis ; (b) the process comprises a step of analysing the sialic acid content of the composition, and: (i) if the composition includes a serogroup W135 saccharide, a step of analysing the galactose content of the composition; (ii) if the composition includes a serogroup Y saccharide, a step of analysing the glucose content of the composition; (c) if the composition includes a serogroup W135 saccharide, the content of serogroup W135 saccharide in the composition is determined according to the results of the galactose analysis from step(b); (d) if the composition includes a serogroup Y saccharide, the content of serogroup Y saccharide in the composition is determined according to the results of the glucose analysis from step (b); and (e) the content of serogroup C saccharide in the composition is determined by comparing the results of the sialic acid analysis with: (i) if the composition includes a serogroup W135 saccharide but not a serogroup Y saccharide, the results of the galactose analysis from step (b); (ii) if the composition includes a serogroup Y saccharide but not a serogroup W135 saccharide, the results of the glucose analysis from step (b) ; or (iii) if the composition includes both a serogroup W135 saccharide and 'a serogroup Y saccharide, the combined results of the glucose and galactose analyses from step (b).
Patent NZ-550352-A (NZ)
Title: Systems and methods for improving livestock production
Inventor: BAUCK STEWART WILLIAM
IPC: G06F19/00
Filed: 2005-04-06
Abstract: A computer-assisted method for improving livestock animal production using a computer system comprising a programmed computer comprising a processor, a data storage system, an input device and an output device is disclosed. The method comprises: (a) inputting into the programmed computer through the input device data comprising a genotype of animals; (b) correlating a physical characteristic predicted by the genotype using the processor and the data storage system; (c) outputting to the output device the physical characteristic correlated to the genotype; (d) segregating the like-genotype animals into groups; (e) feeding the animal groups a diet based upon the physical characteristic predicted by the genotype, thereby improving to improve livestock production through diet; (f) predicting a slaughtering schedule based upon the physical characteristic predicted by the genotype to reduce the time an animal spends on a feed lot, thereby reducing the costs of associated with feeding the animals; (g) slaughtering the animals according to the slaughtering schedule; and (h) profiting from the carcass and/or meat of the animals. The profit from said carcass and/or meat is greater than the profit gained from carcass and/or meat without the use of the computer-assisted method for improving livestock production.
Patent NZ-551810-A (NZ)
Title: CRTH2 receptor ligands for medicinal uses
Inventor: ULVEN TROND
IPC: A61K31/415
Filed: 2005-05-30
Abstract: Disclosed are compounds of formula (I) or a salt, hydrate or solvate thereof, wherein: A represents a carboxyl group -COOH, or a carboxyl bioisostere as defined herein; A1 is hydrogen or methyl; ring Ar1 is a phenyl ring or 5- or 6-membered monocyclic heteroaryl ring, each of which may be optionally substituted; ring Ar2 represents a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; and L2 is a divalent 5-membered heterocyclic radical selected from one of the following formulae, wherein either (i) the bond marked * is attached to Ar2 while the bond marked ** is attached to Ar1 or (ii) the bond marked * is attached to Ar1 while the bond marked ** is attached to Ar2; wherein the remaining substituents are as defined herein. Of particular importance is the compound {4-bromo-2-[1-(2,6-dichlorophenyl)-1H-pyrazole-4-carbonyl]phenoxy}acetic acid. Also disclosed is the use of the compounds as defined above in the manufacture of a composition for the treatment of asthma, rhinitis, allergic airway syndrome, allergic rhinobronchitis, bronchitis, chronic obstructive pulmonary disease (COPD), nasal polyposis, sarcoidosis, farmer's lung, fibroid lung, cystic fibrosis, chronic cough, conjunctivitis, atopic dermatitis, Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Huntington's disease, frontotemporal dementia, Lewy body dementia, vascular dementia, Guillain-Barre syndrome, chronic demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathy, multiple sclerosis, encephalomyelitis, panencephalitis, cerebellar degeneration and encephalomyelitis, GNS trauma, migraine, stroke, rheumatoid arthritis, ankylosing spondylitis, Behcet's Disease, bursitis, carpal tunnel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dermatomyositis, Ehlers-Danlos Syndrome (EDS), fibromyalgia, myofascial pain, osteoarthritis (OA), osteonecrosis, psoriatic arthritis, Reiter's syndrome (reactive arthritis), sarcoidosis, scleroderma, Sjogren's Syndrome, soft tissue disease, Still's Disease, tendinitis, polyarteritis Nodossa, Wegener's Granulomatosis, myositis (polymyositis dermatomyositis), gout, atherosclerosis, lupus erythematosus, systemic lupus erythematosus (SLE), type I diabetes, nephritic syndrome, glomerulonephritis, acute and chronic renal failure, eosinophilia fascitis, hyper IgE syndrome, sepsis, septic shock, ischemic reperfusion injury in the heart, allograft rejection after transplantations, or graft versus host disease.
Patent NZ-552508-A (NZ)
Title: Treatment of cancer with pharmaceutical agents together with anti-Hsp 90 antibodies
Inventor: BURNIE JAMES PETER
IPC: A61K39/395
Filed: 2005-06-30
Abstract: Disclosed is the use of: (i) an antibody or an antigen binding fragment thereof specific for at least one epitope of Hsp90; and (ii) at least one anti-cancer agent selected from the group consisting of: Doxorubicin, Daunorubicin, Epirubicin, Herceptin, Docetaxel, and Cisplatin, or at least one anti-cancer agent selected from the group consisting of: 5-fluorouracil, oxaliplatin, irinotecan and raltitrexed in the manufacture of a medicament for the treatment of cancer, wherein the medicament is formed for simultaneous separate or sequential administration of (i) and (ii). Also disclosed is the use of: (i) an antibody or an antigen binding fragment thereof specific for at least one epitope of Hsp90; and (ii) at least one anti-cancer agent selected from the group consisting of Imatinib, Paclitaxel, Docetaxel, Daunorubicin, Doxorubicin, and Hydroxyurea in the manufacture of a medicament for the treatment of leukaemia, wherein the medicament is formed for simultaneous separate or sequential administration of (i) and (ii).
Patent NZ-552980-A (NZ)
Title: Foldable fish-trap
Filed: 2007-02-01
Abstract: A foldable box-like fish-trap (1) comprising a buoyant upper body (2), a lower body (3), flexible cables (4) attaching the upper body to the lower body, flexible side nets which connect the lower body to the upper body, frames (6, 7) defining at least one fish entrance opening (5) arranged so as to let the fish come in but make it difficult for it to get out, and a bottom (16) formed by a frame and net fixed in an articulated manner to an end of the lower body and releasably fixed at an opposite end of the lower body to make it possible to open the bottom and collect the captured fish.
Patent NZ-553688-A (NZ)
Title: Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase
Inventor: CHAI SIEW YEEN
IPC: A61K31/382
Filed: 2005-09-09
Abstract: Disclosed is the use of a benzopyran of Formula (I) wherein A is aryl, heteroaryl carbocyclyl or heterocyclyl; X is O; R1 is NR7R8, NHCOR8, N(COR8)2, N(COR7)(COR8), N=CHOR8 or N=CHR8 wherein R7 and R8 are independently selected from H, optionally substituted alkyl; R2 is CN, CO2R9, C(O)O(O)R9, C(O)R9 or C(O)NR9R10 wherein R9 and R1O are independently selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl, heterocyclyl; R3 - R9 is independently selected from hydrogen, halo, nitro, cyano alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, carbocyclyl, hydroxy, alkoxy, alkenyloxy, alkynyloxy, alkynyloxy, aryloxy, heteroaryloxy, heterocyclyloxy, amino, acyl, acyloxy, carboxy, carboxyester, methylenedioxy, amido, thio, alkylthio, alkenylthio, alkynylthio, arylthio, heteroarylthio, heterocyclylthio, carbocyclylthio, acylthio and azido, or any two adjacent R3-R6 , together with the atoms to which they are attached, form a 3-8-membered ring; y IS hydrogen or CI-10 alkyl, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for treating memory loss or impairment, or enhancing memory and/or learning.
Patent NZ-555521-A (NZ)
Title: Two-part fence base
Inventor: DEHLSEN BRIAN
Filed: 2007-05-31
Abstract: Two-part fence bases (100) and methods for supporting fences using the bases are disclosed. The base has first (102) and second (104) portions, each consisting of a hollow shell and a settable material filling the shell. This allows the combined weight of the whole base to exceed the maximum permitted weight for safe lifting by a person. When assembled, the second portion is substantially surrounded by the first portion. Part of each portion touches the supporting ground surface when in use.
Patent NZ-556149-A (NZ)
Title: A multilayer dressing made up from fibre non-wovens and at least one water-impermeable polymer layer
Inventor: THIERAUF AXEL
IPC: A61F13/02
Filed: 2005-12-30
Abstract: A multilayer dressing is disclosed. The dressing has a nonwoven layer which is intended to come into contact with a wound and a membrane which is water-impermeable. The membrane includes at least one water insoluble polymer. An adhesive portion which adheres to the skin surrounding the wound may be included on the membrane or the membrane includes no adhesive portion. In the case of the membrane having no adhesive portion, the dressing adheres to the skin surrounding the wound only when an adhesive has been applied to the skin surrounding the wound. The membrane may be bonded to the nonwoven layer in a fashion that is loose and easily broken.
Patent NZ-560435-A (NZ)
Title: Improving embryo development and survival
Inventor: SCHRICK F
IPC: C12N5/073
Filed: 2006-01-13
Abstract: Disclosed is a method for protecting a non-human mammalian embryo from embryotoxic effects of prostaglandin F2alpha comprising exposing an embryo on which a prostaglandin F2alpha receptor is present to a chemical compound that is a prostaglandin F2alpha receptor antagonist in an amount and for a time sufficient to protect the embryo from the embryotoxic effects of prostaglandin F2alpha.
Patent NZ-561669-A (NZ)
Title: A heat exchanger
Inventor: WEEL KEES
Filed: 2007-09-19
Abstract: A heat exchanger is described such as for cooling air by using water, particularly for use as an intercooler in an internal combustion engine. The heat exchanger has an elongate and preferably cylindrical core assembly housed within a shell. The core assembly has a plurality of spaced apart tubes extending between a first inlet, for introducing the air into the tubes, and a first outlet, for exit of the air from the tubes; a plurality of flow means disposed between and in thermal contact with the tubes, the flow means adapted to pass water across the core assembly generally at right angles to the air flow to transfer heat between the tubes and the water; and baffles so that water enters the core assembly by a second inlet, propagates through the core assembly generally in the direction of the air flow axis, wherein the baffles cause the water to move along in a tortuous path, along which the water absorbs heat from the tubes to cool the air. Preferably, the baffles are alternatingly disposed along opposite sides of the core assembly, the baffles being of generally semicircular shape and configured to sealingly engage with the shell so as to define a plurality of adjacent longitudinal sections along the length of the core assembly arranged so that the water is able to move between respective adjacent longitudinal sections only on the side of the core assembly opposite to a respective baffle.
Patent NZ-562736-A (NZ)
Title: Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
Inventor: PHELPS CAROL J
IPC: C12N5/06
Filed: 2003-08-21
Abstract: Disclosed is a method for a method for producing an alpha 1,3 GT deficient non-human animal comprising: (a) exposing a population of cells to Clostridium difficile toxin A; (b) removing cells which lift from the surface matrix because they are adversely affected by toxin A due to the receptor-mediated cytotoxicity of the toxin; (c) expanding and maintaining those cells which do not show the effects of receptor-mediated cytotoxicity; (d) using these toxin A-resistant cells as nuclear donors for nuclear transplantation into a suitable recipient cell; (e) implanting the fused and activated cells into a female surrogate; and (f) producing a cloned animal which exhibits a deficiency or complete lack of alpha1,3-gal epitopes on its cell surfaces. Further disclosed are animals, tissues, organs and cells produced by this method which can be used in research and in medical therapy, including in xenotransplantation.
Patent NZ-565749-A (NZ)
Title: Pyrazine derivatives and use as PI3K inhibitors
Inventor: GAILLARD PASCALE
IPC: A61K31/498
Filed: 2006-08-25
Abstract: Disclosed are pyrazine derivatives of formula (I) wherein A, B, D and e are independently selected from C and N and the remaining substituents are as defined in the specification, and their use in treating diseases such as autoimmune and inflammatory disorders, cardiovascular, neurodegenerative and kidney diseases.
Patent NZ-566251-A (NZ)
Title: Locatable and information sound device and method
Inventor: WITHINGTON DEBORAH JANE
IPC: G08B3/10
Filed: 2006-07-13
Abstract: A device which is adapted to emit sequentially a locating sound signal comprising broad band sound and an information sound signal comprising at least verbal information is provided.
Patent NZ-566865-A (NZ)
Title: Package integrity indicating closure
Inventor: COLE CAROLE A
IPC: B65D77/20
Filed: 2008-03-20
Abstract: A resealable closure for a container in which package integrity is indicated by a structure which breaks and/or produces an audible sound when the resealable closure is opened for a first time. The package integrity feature, in one form includes at least one strip initially affixed to two portions which comprise the resealable closure so that upon opening the resealable closure for a first time, at least one of the strips breaks, thereby producing the audible sound. The strips may include a weakened portion such as a narrowing. Integrity of the package is indicated by an intact strip viewable upon opening the resealable closure and conversely, a broken or non-intact strip would indicate that the resealable closure has been previously opened. Package integrity may also be shown by a movable second panel or movable die cut tab portions.
Patent NZ-573032-A (NZ)
Title: Antimicrobial heretocyclic compound and intermediates for its production
Inventor: ANDO JUNICHI
IPC: A61K31/4375
Filed: 2007-05-24
Abstract: Disclosed is an oxo-substituted fused heterocyclic bicyclic ring derivative of Formula 1, wherein the substituents are as defined in the specification. Also disclosed is the use of the compound as an antimicrobial agent, against gram-positive bacteria, gram-negative bacteria, and resistant bacteria. Also disclosed are processes for producing the compound of Formula 1 and intermediates used in its preparation.
Patent NZ-574177-A (NZ)
Title: Device for switching the flow to an underwater turbine between a first flow and a second flow alternately
Inventor: PENTIKAINEN ISMO
IPC: F03B15/06
Filed: 2007-07-04
Abstract: The present invention refers to a hydromechanical device arranged to be provided in a stream of water (w) for generating power. A first inlet conduit (1) is arranged to convey a first flow of water. A second inlet conduit (2) is arranged to convey a second flow of water. A switching device (3) is provided immediately downstream the inlet conduits. A turbine (4) is provided downstream the switching device. The switching device is arranged to convey in an alternating order, the first flow and the second flow to the turbine in such a way that the first flow and the second flow alternately drives the turbine.
Patent NZ-576782-A (NZ)
Title: Pyrido[2,3-b]indol derivatives as kinase inhibitors
Inventor: BROWN JASON W
IPC: C07D471/04
Filed: 2007-10-08
Abstract: Disclosed are pyrido[2,3-b]indol derivatives which are useful as kinase inhibitors, and are as represented by the general formula (I), wherein the substituents are as defined herein. Representative compounds include 2-((3-(5-(3-(cyclopropylcarbamoyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; 2-((3-(5-(3-(ethylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(methyl)amino)ethanol, 2-((3-(5-(3-(cyclopropylsulfonyl)phenyl)-3-methyl-9Hpyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate, 2-((3-(5-(3-(ethylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(methyl)amino)ethyl dihydrogen phosphate and 2-((3-(5-(3-(cyclopropylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate. Further disclosed is a pharmaceutical composition which comprises as an active ingredient, a compound as defined above, together with a pharmaceutically acceptable carrier, for the treatment of conditions such as cancer, squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, non small-cell lung cancer, bladder cancer, head and neck cancer, melanoma, etc., inflammation, inflammatory bowel disease, psoriasis, transplant rejection, amyotrophic lateral sclerosis, corticobasal degeneration, Down's syndrome, Huntington's Disease, Parkinson's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, dementia related diseases, Alzheimer's Disease, hair loss and as a contraceptive medication.
Patent NZ-579170-A (NZ)
Title: Reducing side effects of tramadol
Inventor: BAR-OR DAVID
IPC: A61K31/135
Filed: 2008-02-12
Abstract: Disclosed is a composition comprising tramadol, a PDE5 inhibitor and a pharmaceutically acceptable carrier. The composition is used to treat the side effects of erectile dysfunction, anorgasmia, penile hypoesthesia, decreased libido or decreased orgasmic sensation which occur when tramadol is taken.
Patent NZ-580938-A (NZ)
Title: Composition and methods of use for treatment of mammalian diseases
Inventor: SABIN ROBERT
IPC: A61K9/50
Filed: 2005-07-08
Abstract: Disclosed is a chemical composition comprising: a core essentially of a biologically acceptable copper compound, wherein said copper compound is a fixed copper compound, said core being encapsulated, encoated, enclosed, adsorbed, complexed or bound in at least one of a sheath, a shell, a polymeric shell, a jacket, or combination thereof, and, a pharmaceutically acceptable carrier. Also disclosed is a method of preparing said compositions. (62) Divided Out of 552451
Patent NZ-582595-A (NZ)
Title: Low-additive influenza vaccines
Inventor: VORLOP JUERGEN
IPC: A61K39/145
Filed: 2008-06-27
Abstract: Disclosed is a sterile influenza vaccine lacks at least three of: a mercurial preservative; an antibiotic; formaldehyde; and egg-derived materials. In some embodiments, the vaccine includes none of these four components.
Patent NZ-585634-A (NZ)
Title: A translucent colour coded liner for a wire mesh cable tray system
Inventor: OGDEN BRUCE JAMES
IPC: F16L3/06
Filed: 2010-05-26
Abstract: Disclosed is a cable tray system including a wire mesh cable tray which defines an elongate channel for receiving a bundle of cables and a liner which extends along a base surface of the channel. The liner is formed of a translucent sheet material and is a specific colour selected to identify the type of cable which is located in the cable tray.
Patent NZ-591566-A (NZ)
Title: Arrangement and method to retrofit a wind turbine wherein the blade extension is connected to a tip of the wind turbine by way of a vacuum fit
Inventor: STEGE JASON
IPC: B32B37/10
Filed: 2011-03-04
Abstract: A retrofitted wind turbine arrangement is disclosed. The arrangement comprises a wind turbine blade (1) and a blade extension (2). The blade extension (2) is connected to a tip of the wind turbine blade (1) at least partly by way of a vacuum fit. The pressure in a cavity (3) between a part of the tip of the wind turbine blade (1) and the blade extension (2) is less than the ambient barometric pressure.
Patent NZ-593374-A (NZ)
Title: Process of microbic biotechnology for completely degrading gluten in flours using a mixture of lactobacillus sanfranciscensis dsm22063 and lactobacillus plantarum dsm22064
Inventor: GIULIANI GIAMMARIA
IPC: A21D8/04
Filed: 2009-12-17
Abstract: Patent No. 593374 Disclosed is a mixture comprising or consisting of Lactobacillus sanfranciscensis DSM22063 and Lactobacillus plantarum DSM 22064 lactic acid bacteria. Also disclosed is a process for the preparation of a dough in which gluten is completely liquid flour degraded and which is suitable for the production of leavened gluten-free products, comprising or consisting of the following steps of: a) culture propagating Lactobacillus sanfranciscensis DSM22063 and Lactobacillus plantarum DSM 22064 lactic acid bacteria; b) mixing 20-50% by weight flour and 50-80% by weight water, wherein the % weight is based on the total weight of the flour and water, with the two bacteria strains of a) step at a cellular density of about 10^8 cfu/g; c) adding one or more fungal proteases, each at a concentration of 200-500 ppm; and d) fermenting for 8-20 h at 30-37 degree C to obtain a liquid dough.